🔎 Trials Near Me

Home › Metastatic Cancer › Virginia › Richmond

Pag-aaral pangklinika para sa Metastatic Cancer sa Richmond, VA

Isang pag-aaral para sa Metastatic Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Richmond. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Nagre-recruitPhase 2
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Lahat ng edad · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564377

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Nagre-recruitPhase 3
  • Virginia Cancer Institute, Richmond
  • Virginia Cancer Institute, Richmond
  • Virginia Cancer Institute, Mechanicsville · 6 mi ang layo
  • at 2 pa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07222800

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Nagre-recruitPhase 3
  • Research Site, Midlothian · 11 mi ang layo
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07647328

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Nagre-recruitPhase 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06119581

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Nagre-recruitPhase 2
  • VCU Massey Comprehensive Cancer Center, Richmond
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06311214

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Nagre-recruitPhase 2
  • Virginia Commonwealth University Massey Cancer Center, Richmond
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06769698

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Nagre-recruitPhase 3
  • Research Site, Richmond
Edad 18 pataas · Kababaihan · Na-update Hul 29, 2026 · NCT07044336

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Nagre-recruitPhase 3
  • Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update May 18, 2026 · NCT06757634

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Nagre-recruitPhase 2/3
  • Virginia Commonwealth University, Richmond
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06947928

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Nagre-recruitPhase 3
  • VCU Massey Cancer Center, Richmond
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06064877

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Nagre-recruitPhase 2/3
  • Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond
Edad 18 pataas · Kalalakihan · Na-update Abr 8, 2026 · NCT04787744

Pag-aaral para sa Metastatic Cancer sa ibang lungsod

Iba pang pag-aaral sa Richmond

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.